EGFR and non-small cell lung carcinoma: In Taiwan, non-small cell lung cancer (NSCLC) patients have a more than 50% response rate to treatment involving epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) because of a high incidence of somatic activating mutations [3–6].